Pankaj Wanjarkhedkar
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Pankaj Wanjarkhedkar has a total of 17 co-authors. Here are the top co-authors by number of shared publications:
Dhananjay Kelkar
Surgical Oncology, VLM Cancer Center, Deenanath Mangeshkar Hospital & Research Center, Pune, MH, India
6 shared publicationsSachin Hingmire
Medical Oncology, VLM Cancer Center, Deenanath Mangeshkar Hospital & Research Center, Pune, MH, India
4 shared publicationsBharat Purandare
Department of Infectious Disease, Deenanath Mangeshkar Hospital & Research Center, Pune, MH, India
2 shared publicationsChetan Deshmukh
Medical Oncology, VLM Cancer Center, Deenanath Mangeshkar Hospital & Research Center, Pune, MH, India
2 shared publicationsGirish Sarade
Department of Ayurveda & Integrative Medicine, Deenanath Mangeshkar Hospital & Research Center, Pune, MH, India
2 shared publicationsKamlesh Bokil
Dwidal Nursing Home, Pune, Maharashtra, India
2 shared publications
Latest Publications
- Open Access
- 17 May 2023
- Published by Elsevier in Journal of Ayurveda and Integrative Medicine
- Vol. 14 (5) , 100714
Integrative Cancer Care Unit: An institutional experiment towards Integrative Oncology
- 17 May 2023
- Published by Elsevier in Journal of Ayurveda and Integrative Medicine
- Vol. 14 (5) , 100714
Open AccessIntegrative Cancer Care Unit: An institutional experiment towards Integrative Oncology
- Open Access
- 21 April 2022
- Published by Georg Thieme Verlag KG in Indian Journal of Medical and Paediatric Oncology
- Vol. 43 (05) , e1
Erratum to: Ayurveda Maintenance Therapy in Recurrent Ovarian Cancer
The authors have informed the Publisher about an update in the above-mentioned article. The DOI of the original article is: https://doi.org/10.1055/s-0041-1740323 (published efirst on February 2, 2022). The changes are presented in bold in the following two sentences: Publication Date: 21 April 2022 (online) © 2022. Indian Society of Medical and Paediatric Oncology. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/) Thieme Medical and Scientific Publishers Pvt. Ltd. A-12, 2nd Floor, Sector 2, Noida-201301 UP, India
- 21 April 2022
- Published by Georg Thieme Verlag KG in Indian Journal of Medical and Paediatric Oncology
- Vol. 43 (05) , e1
Open AccessErratum to: Ayurveda Maintenance Therapy in Recurrent Ovarian Cancer
The authors have informed the Publisher about an update in the above-mentioned article. The DOI of the original article is: https://doi.org/10.1055/s-0041-1740323 (published efirst on February 2, 2022). The changes are presented in bold in the following two sentences: Publication Date: 21 April 2022 (online) © 2022. Indian Society of Medical and Paediatric Oncology. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/) Thieme Medical and Scientific Publishers Pvt. Ltd. A-12, 2nd Floor, Sector 2, Noida-201301 UP, India
- Open Access
- 6 April 2022
- Published by Elsevier in Journal of Ayurveda and Integrative Medicine
- Vol. 13 (3) , 100575
The Post-COVID 19 long term surveillance study sequel to an add-on Ayurveda regimen
- 6 April 2022
- Published by Elsevier in Journal of Ayurveda and Integrative Medicine
- Vol. 13 (3) , 100575
Open AccessThe Post-COVID 19 long term surveillance study sequel to an add-on Ayurveda regimen
- Open Access
- 2 February 2022
- Published by Georg Thieme Verlag KG in Indian Journal of Medical and Paediatric Oncology
- Vol. 43 (05) , 434-438
Ayurveda Maintenance Therapy in Recurrent Ovarian Cancer
Despite optimal surgery and first-line platinum-based doublet chemotherapy, approximately 70 to 80% of patients with epithelial ovarian cancers relapse. Two cases of recurrent ovarian cancer (ROC) were treated with non–platinum-based Ayurveda maintenance therapy (AMT) consisting of drugs having a herbal and herbomineral origin. This regimen was followed over a period of 3 years and progression-free survival (PFS) was noted along with platinum-free interval (PFI). Two patients were diagnosed with BRCA1 mutated recurrent high-grade serous ovarian carcinoma and treated with the per-oral AMT regimen labeled as ZINCA-30 in our hospital after completion of standard of care treatment and followed up until progression. The ZINCA-30 regimen comprising Jasada (traditional Zinc preparation), Indukanth kwatham and Curcuma amada powder in combination was prescribed based on Rasayana chikitsa postulated in Ayurveda. The patients were followed up every 3 months. The progression-free survival observed in these patients was 28 months and 45 months, respectively. These two pilot cases suggested an increased platinum-free interval (PFI), improved progression-free survival (PFS) in recurrent ovarian cancer (ROC), with the AMT labeled as ZINCA-30 after chemotherapy.
- 2 February 2022
- Published by Georg Thieme Verlag KG in Indian Journal of Medical and Paediatric Oncology
- Vol. 43 (05) , 434-438
Open AccessAyurveda Maintenance Therapy in Recurrent Ovarian Cancer
Despite optimal surgery and first-line platinum-based doublet chemotherapy, approximately 70 to 80% of patients with epithelial ovarian cancers relapse. Two cases of recurrent ovarian cancer (ROC) were treated with non–platinum-based Ayurveda maintenance therapy (AMT) consisting of drugs having a herbal and herbomineral origin. This regimen was followed over a period of 3 years and progression-free survival (PFS) was noted along with platinum-free interval (PFI). Two patients were diagnosed with BRCA1 mutated recurrent high-grade serous ovarian carcinoma and treated with the per-oral AMT regimen labeled as ZINCA-30 in our hospital after completion of standard of care treatment and followed up until progression. The ZINCA-30 regimen comprising Jasada (traditional Zinc preparation), Indukanth kwatham and Curcuma amada powder in combination was prescribed based on Rasayana chikitsa postulated in Ayurveda. The patients were followed up every 3 months. The progression-free survival observed in these patients was 28 months and 45 months, respectively. These two pilot cases suggested an increased platinum-free interval (PFI), improved progression-free survival (PFS) in recurrent ovarian cancer (ROC), with the AMT labeled as ZINCA-30 after chemotherapy.
- Open Access
- 1 January 2022
- Published by Elsevier in Journal of Ayurveda and Integrative Medicine
- Vol. 13 (1) , 100365
A prospective clinical study of an Ayurveda regimen in COVID 19 patients
- 1 January 2022
- Published by Elsevier in Journal of Ayurveda and Integrative Medicine
- Vol. 13 (1) , 100365
Open AccessA prospective clinical study of an Ayurveda regimen in COVID 19 patients
- Open Access
- 1 October 2020
- Published by Scientific Scholar in South Asian Journal of Cancer
- Vol. 09 (04) , 250-252
An Ayurveda Gargle Regimen in Management of Radiotherapy-induced Oral Mucositis
Background Radiotherapy-induced oral mucositis (RIOM) in patients with head and neck cancer may lead to significant morbidity. OM may result in erythema, ulceration, and pseudomembrane formation. The usual time of onset is second or third week of radiotherapy (RT), after the doses of 16 to 18 Gy. OM may cause severe pain, significant weight loss, increased resource use, interruption or discontinuation of the treatment, and added cost of supportive care. Materials and Methods Patients who underwent RT and chemoradiation (CTRT) for head and neck squamous cell carcinoma (HNSCC) from 2015 to 2016 were included. The patients who were treated with the add-on Ayurveda gargle regimen (AGR) of sapthachhadadi gandoosham were evaluated against patients treated with standard symptomatic care (SSC). Statistical Analysis Chi-square test was used to compare the difference between the two groups in the present study with SPSS (SPSS version 20 for Windows package SPSS Science, Chicago, IL, USA). software. Result Grade III to IV OM was lower in the AGR group when compared with the SSC group (p < 0.001). Onset of OM was significantly delayed in patients from the AGR group (p < 0.001). Conclusion The AGR with sapthachhadadi gandoosham is effective in delaying the onset and reducing severity of OM in HNSCC, without compromising the rate of locoregional recurrence.
- 1 October 2020
- Published by Scientific Scholar in South Asian Journal of Cancer
- Vol. 09 (04) , 250-252
Open AccessAn Ayurveda Gargle Regimen in Management of Radiotherapy-induced Oral Mucositis
Background Radiotherapy-induced oral mucositis (RIOM) in patients with head and neck cancer may lead to significant morbidity. OM may result in erythema, ulceration, and pseudomembrane formation. The usual time of onset is second or third week of radiotherapy (RT), after the doses of 16 to 18 Gy. OM may cause severe pain, significant weight loss, increased resource use, interruption or discontinuation of the treatment, and added cost of supportive care. Materials and Methods Patients who underwent RT and chemoradiation (CTRT) for head and neck squamous cell carcinoma (HNSCC) from 2015 to 2016 were included. The patients who were treated with the add-on Ayurveda gargle regimen (AGR) of sapthachhadadi gandoosham were evaluated against patients treated with standard symptomatic care (SSC). Statistical Analysis Chi-square test was used to compare the difference between the two groups in the present study with SPSS (SPSS version 20 for Windows package SPSS Science, Chicago, IL, USA). software. Result Grade III to IV OM was lower in the AGR group when compared with the SSC group (p < 0.001). Onset of OM was significantly delayed in patients from the AGR group (p < 0.001). Conclusion The AGR with sapthachhadadi gandoosham is effective in delaying the onset and reducing severity of OM in HNSCC, without compromising the rate of locoregional recurrence.